Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment

Cell- based targeted delivery is recently gain attention as a promising platform for delivery of anticancer drug in selective and efficient manner. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical application as targeted drug delivery system (TDDS). In the current work,...

Full description

Bibliographic Details
Main Authors: Sameh Rabea, Fars K. Alanazi, Abdelkader E. Ashour, Mounir M. Salem-Bekhit, Aymen S. Yassin, Nayera A. Moneib, Abd Elgawad M. Hashem, Nazrul Haq
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:Saudi Pharmaceutical Journal
Subjects:
Online Access:http://www.sciencedirect.com/science/article/pii/S131901642030195X
id doaj-6d35c9fb80a64fb091af9efb1ed3edd4
record_format Article
spelling doaj-6d35c9fb80a64fb091af9efb1ed3edd42020-11-25T03:37:09ZengElsevierSaudi Pharmaceutical Journal1319-01642020-10-01281012531262Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatmentSameh Rabea0Fars K. Alanazi1Abdelkader E. Ashour2Mounir M. Salem-Bekhit3Aymen S. Yassin4Nayera A. Moneib5Abd Elgawad M. Hashem6Nazrul Haq7College of Pharmacy, Al-Maarefa University, P.O. Box 71666, Riyadh 11597, Saudi ArabiaKayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Corresponding author.Department of Basic Medical Sciences, Kulliyyah of Medicine, International Islamic University Malaysia, Bandar Indera Mahkota Campus, Pahang Darul Makmur, MalaysiaKayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi Arabia; Department of Microbiology and Immunology, Faculty of Pharmacy, Al-Azhar University, Cairo, EgyptDepartment of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11652, EgyptDepartment of Microbiology and Immunology, Faculty of Pharmacy, Cairo University, Cairo 11652, EgyptFaculty of Pharmacy, British University in Egypt (BUE), Cairo 11837, P.O. Box 43, EgyptKayyali Chair for Pharmaceutical Industry, Department of Pharmaceutics, College of Pharmacy, King Saud University, P.O. Box 2457, Riyadh 11451, Saudi ArabiaCell- based targeted delivery is recently gain attention as a promising platform for delivery of anticancer drug in selective and efficient manner. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical application as targeted drug delivery system (TDDS). In the current work, Salmonellas’ BGs was utilized for the first time as hepatocellular cancer (HCC) in-vitro targeted delivery system. Successful BGs loading and accurate analysis of doxorubicin (DOX) were necessary steps for testing the applicability of DOX loaded BGs in targeting the liver cancer cells. Loading capacity was maximized to reach 27.5 µg/mg (27.5% encapsulation efficiency), by incubation of 10 mg BGs with 1 mg DOX at pH 9 in constant temperature (25 °C) for 10 min. In-vitro release study of DOX loaded BGs showed a sustained release (182 h) obeying Higuchi sustained kinetic release model. The death rate (tested by MTT assay) of HepG2 reached to 64.5% by using of 4 μg/ml, while it was about 51% using the same concentration of the free DOX (P value < 0.0001 One-way ANOVA analysis). The proliferative inhibitory concentration (IC50) of the DOX combined formula was 1.328 µg/ml that was about one third of the IC50 of the free DOX (3.374 μg/ml). Apoptosis analysis (tested by flow-cytometry) showed more accumulation in early apoptosis (8.3%) and late apoptosis/necrosis (91%) by applying 1 μg/ml BGs combined DOX, while 1 μg/ml free DOX showed 33.4% of cells in early apoptosis and 39.3% in late apoptosis/necrosis, (P value˃ 0.05: one-way ANOVA). In conclusion, DOX loaded Salmonellas’ BGs are successfully prepared and tested in vivo with promising potential as hepatocellular cancer (HCC) targeted delivery system.http://www.sciencedirect.com/science/article/pii/S131901642030195XBacterial ghostsSalmonellaCell based deliveryLiver cancerTargeted drug delivery system
collection DOAJ
language English
format Article
sources DOAJ
author Sameh Rabea
Fars K. Alanazi
Abdelkader E. Ashour
Mounir M. Salem-Bekhit
Aymen S. Yassin
Nayera A. Moneib
Abd Elgawad M. Hashem
Nazrul Haq
spellingShingle Sameh Rabea
Fars K. Alanazi
Abdelkader E. Ashour
Mounir M. Salem-Bekhit
Aymen S. Yassin
Nayera A. Moneib
Abd Elgawad M. Hashem
Nazrul Haq
Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
Saudi Pharmaceutical Journal
Bacterial ghosts
Salmonella
Cell based delivery
Liver cancer
Targeted drug delivery system
author_facet Sameh Rabea
Fars K. Alanazi
Abdelkader E. Ashour
Mounir M. Salem-Bekhit
Aymen S. Yassin
Nayera A. Moneib
Abd Elgawad M. Hashem
Nazrul Haq
author_sort Sameh Rabea
title Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
title_short Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
title_full Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
title_fullStr Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
title_full_unstemmed Salmonella-innovative targeting carrier: Loading with doxorubicin for cancer treatment
title_sort salmonella-innovative targeting carrier: loading with doxorubicin for cancer treatment
publisher Elsevier
series Saudi Pharmaceutical Journal
issn 1319-0164
publishDate 2020-10-01
description Cell- based targeted delivery is recently gain attention as a promising platform for delivery of anticancer drug in selective and efficient manner. As a new biotechnology platform, bacterial ghosts (BGs) have novel biomedical application as targeted drug delivery system (TDDS). In the current work, Salmonellas’ BGs was utilized for the first time as hepatocellular cancer (HCC) in-vitro targeted delivery system. Successful BGs loading and accurate analysis of doxorubicin (DOX) were necessary steps for testing the applicability of DOX loaded BGs in targeting the liver cancer cells. Loading capacity was maximized to reach 27.5 µg/mg (27.5% encapsulation efficiency), by incubation of 10 mg BGs with 1 mg DOX at pH 9 in constant temperature (25 °C) for 10 min. In-vitro release study of DOX loaded BGs showed a sustained release (182 h) obeying Higuchi sustained kinetic release model. The death rate (tested by MTT assay) of HepG2 reached to 64.5% by using of 4 μg/ml, while it was about 51% using the same concentration of the free DOX (P value < 0.0001 One-way ANOVA analysis). The proliferative inhibitory concentration (IC50) of the DOX combined formula was 1.328 µg/ml that was about one third of the IC50 of the free DOX (3.374 μg/ml). Apoptosis analysis (tested by flow-cytometry) showed more accumulation in early apoptosis (8.3%) and late apoptosis/necrosis (91%) by applying 1 μg/ml BGs combined DOX, while 1 μg/ml free DOX showed 33.4% of cells in early apoptosis and 39.3% in late apoptosis/necrosis, (P value˃ 0.05: one-way ANOVA). In conclusion, DOX loaded Salmonellas’ BGs are successfully prepared and tested in vivo with promising potential as hepatocellular cancer (HCC) targeted delivery system.
topic Bacterial ghosts
Salmonella
Cell based delivery
Liver cancer
Targeted drug delivery system
url http://www.sciencedirect.com/science/article/pii/S131901642030195X
work_keys_str_mv AT samehrabea salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT farskalanazi salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT abdelkadereashour salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT mounirmsalembekhit salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT aymensyassin salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT nayeraamoneib salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT abdelgawadmhashem salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
AT nazrulhaq salmonellainnovativetargetingcarrierloadingwithdoxorubicinforcancertreatment
_version_ 1724546879341985792